HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Hydroxychloroquine & COVID 19: Is It a Clinical "Bear Market" for the Drug?

Jason Pogue, PharmD, BCPS, BCIDP, answers questions about the emerging picture for hydroxychloroquine.

Segment Description: Jason Pogue, PharmD, BCPS, BCIDP, clinical pharmacist and professor in infectious diseases at the University of Michigan College of Pharmacy, speaks with Contagion about the emerging picture for hydroxychloroquine, a now-controversial drug which made headlines after showing promise in the lab against SARS-CoV-2.

The debate has been complicated in recent days, after The New England Journal of Medicine and The Lancet had authors issue retractions of articles based on a potentially faulty data source. The contested articles came from a database which cannot be verified. The results also showed what some view as an unrealistic level of harm from the drug, even among hydroxychloroquine skeptics.

A different publication, on use of the drug for out-patient prophylaxis, has offered less contested insight.